Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center
Our results indicate that systemic therapy can provide durable disease control in selected patients with chordoma. TKI are commonly used and may provide good responses while ICIs show potential activity in selected patients but await confirmation in robust clinical trials. These real-world data reinforce the need for prospective, multicenter studies to optimize treatment sequencing and patient selection in this rare malignancy.
Authors
- Francesc Feliu Torrent
- Javier González-Viguera (ORCID: https://orcid.org/0000-0001-9750-4667)
- O. Pablos
- Luis Jimenez
- Juan Carlos Sardiñas
- Xavier Sanjuán (ORCID: https://orcid.org/0000-0002-5253-822X)
- Juan Martín-Liberal (ORCID: https://orcid.org/0000-0003-2552-5172)
- Federico Portabella
- X. Garcia Del Muro
- Javier Hernández (ORCID: https://orcid.org/0009-0000-4056-4239)
- María Luisa Fontalva
- Mario Balsa
- Alicia Lozano
- Diana Pérez
- Ma Rosa Comabella
- Rosó Sala
- Gianni Ippoliti
- Jose Antonio Narváez
- Joan Maria Viñals
- Alejandro Ruiz
Institutions
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Institut Català d'Oncologia (ES)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.3389/fonc.2026.1755538
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centres de Recerca de Catalunya
- Generalitat de Catalunya